104 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by GAMMA Investing LLC

GAMMA Investing LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 104 shares of the company’s stock, valued at approximately $30,000.

Other large investors have also added to or reduced their stakes in the company. Contravisory Investment Management Inc. bought a new position in Medpace during the fourth quarter valued at $26,000. RiverPark Advisors LLC purchased a new stake in Medpace during the fourth quarter valued at about $26,000. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Medpace during the 4th quarter valued at approximately $33,000. Daiwa Securities Group Inc. boosted its holdings in Medpace by 213.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 345 shares of the company’s stock worth $105,000 after buying an additional 235 shares during the period. Finally, Integrated Investment Consultants LLC purchased a new position in Medpace in the 4th quarter valued at approximately $201,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.4 %

MEDP stock opened at $392.57 on Monday. The company’s 50 day moving average is $398.08 and its 200 day moving average is $331.78. The stock has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.27 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MEDP shares. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and raised their target price for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Guggenheim upped their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Finally, Robert W. Baird increased their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock valued at $82,702,867 over the last quarter. Corporate insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.